Explore this article's sources with AI
Follow PeptideMethods on Google
GLP-1 Drugs for Antipsychotic Weight Gain
A 2026 meta-analysis found GLP-1 drugs reduced antipsychotic-related weight and metabolic measures, with more gastrointestinal side effects.
Why we wrote this. This review gives patients and clinicians a pooled estimate while making the gastrointestinal and psychiatric-safety limits clear.
In this article (5 sections)
A meta-analysis published on 24 October 2026 found that GLP-1 receptor agonists reduced body weight by an average of 6.54 kg compared with control treatment in adults taking antipsychotic medicines. The estimate came from eight randomized controlled trials with 535 participants. The same review found more nausea, vomiting, and constipation among people assigned a GLP-1 drug, while psychiatric safety remained too sparsely reported for a firm conclusion[1].
The pooled results
The authors searched six research databases and trial registries through 13 September 2026. They included randomized trials of adults receiving antipsychotic treatment and combined the results with random-effects models, a method designed to account for differences among studies. The primary outcomes were body weight, body mass index (BMI), HbA1c, and total cholesterol. HbA1c is a blood test that reflects average blood glucose over roughly two to three months[1].
Across the eight trials, GLP-1 treatment was associated with a 6.54 kg greater reduction in body weight and a 2.34 kg/m² greater reduction in BMI than control treatment. The pooled estimate for waist circumference was 5.22 cm lower, while visceral fat mass was 0.31 kg lower. HbA1c fell by 0.32 percentage points and LDL cholesterol fell by 0.16 mmol/L. The review did not find statistically significant differences in total cholesterol, triglycerides, or HDL cholesterol[1].
The body-weight result varied markedly among the trials. Its I² value was 92%, a measure indicating that most of the observed variation was unlikely to come from sampling error alone. BMI also showed substantial variation, with an I² value of 85%. These pooled averages describe the included trial populations. They do not promise the same result for an individual patient, a particular antipsychotic, or every GLP-1 medicine[1].
Semaglutide led the subgroup result
In subgroup analyses, weight reduction was greatest with semaglutide, followed by liraglutide. Longer treatment duration was also associated with a larger reduction. The abstract reports that both subgroup differences met the authors' threshold for statistical significance, but it does not provide the drug-specific pooled kilogram estimates. That limits how precisely readers can compare the medicines from the abstract alone[1].
One of the trials behind the pooled evidence was HISTORI, a 30-week study of 154 adults with schizophrenia, prediabetes, and overweight or obesity who were taking second-generation antipsychotics. Semaglutide reduced body weight by 9.21 kg and HbA1c by 0.46 percentage points compared with placebo. It did not significantly change the trial's measure of schizophrenia symptoms. Gastrointestinal symptoms occurred more often with semaglutide[2]. Readers looking for the broader evidence and prescription status can use our semaglutide evidence page. The meta-analysis still provides the better estimate across the full group of eight trials[1].
Gastrointestinal effects were more common
Nausea was 1.61 times as likely with GLP-1 treatment as with control treatment. Vomiting was 2.10 times as likely, and constipation was 2.34 times as likely. The analysis did not detect statistically significant differences in diarrhea, serious adverse events, all-cause discontinuation, or discontinuation caused by adverse events. A result that is not statistically significant does not prove that the risks are identical. It means this analysis did not establish a difference[1].
The serious-adverse-event estimate had a risk ratio of 0.72 with a 95% confidence interval from 0.49 to 1.06. Discontinuation caused by adverse events had a risk ratio of 2.14, but its confidence interval ran from 0.72 to 6.33. Because both intervals cross 1.0, each estimate remains compatible with no difference as well as with clinically relevant differences in either direction. The width of the discontinuation interval shows how imprecise that result was[1].
What the review cannot establish
Psychiatric adverse events were infrequent and could not be pooled. The authors therefore concluded that psychiatric safety could not be established from the available trials. That gap deserves attention because the participants were taking antipsychotic medicines for severe mental illness. A pooled improvement in weight or blood glucose cannot answer whether treatment affects psychiatric symptoms, relapse, or other mental-health outcomes when those events are reported inconsistently[1].
The evidence base was also small: eight trials and 535 randomized participants. It combined different GLP-1 drugs, treatment durations, and study populations, which helps explain the high variation in the weight and BMI estimates. Its authors called for longer trials with standardized safety reporting. Until those data arrive, the 6.54 kg pooled result is best read as evidence of an average benefit across this set of trials, not a settled estimate for every clinical situation[1].
What this means for care
The review supports GLP-1 receptor agonists as a treatment option clinicians may consider for antipsychotic-related weight and metabolic problems. It also leaves a practical tradeoff: average improvements in weight and waist size, along with HbA1c, came with more gastrointestinal adverse events. Decisions still need to account for the person's antipsychotic regimen, metabolic health, other medicines, and ability to tolerate treatment. This evidence does not support starting, stopping, or changing either medicine without the prescribing team[1].
For patients and families, the useful questions are concrete. Ask which outcome the treatment is meant to improve and how weight and blood tests will be monitored. Ask separately which adverse effects should prompt a call to the clinic. The review gives clinicians a stronger pooled estimate for metabolic outcomes, but its limited psychiatric safety data make coordinated follow-up especially important[1].
Frequently asked
How much weight did GLP-1 drugs reduce in the review?
Across eight randomized trials, the pooled difference was 6.54 kg in favor of GLP-1 receptor agonists versus control treatment. Results varied substantially among trials, so the average does not predict an individual's response.
Which GLP-1 drug had the largest effect?
The review's subgroup analysis found the greatest weight reduction with semaglutide, followed by liraglutide. The abstract did not report a separate pooled kilogram estimate for each drug.
Were GLP-1 drugs safe with antipsychotics?
Nausea, vomiting, and constipation were more common with GLP-1 treatment. Serious adverse events and discontinuation did not differ significantly, while psychiatric safety could not be established because those events were reported too sparsely.
Sources
- [1]Zhou et al. (2026): GLP-1 receptor agonists for antipsychotic-related overweight and metabolic dysregulation, systematic review and meta-analysis (PMID 42920001)Tier 1 · primary↩
- [2]Ganeshalingam et al. (2025): Semaglutide in antipsychotic-treated patients with schizophrenia, prediabetes, and obesity, the HISTORI randomized clinical trial (PMID 40900607)Tier 1 · primary↩
No revisions yet. First published .